Filtered By:
Specialty: Cardiology
Condition: Ischemic Stroke
Drug: Plavix

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 352 results found since Jan 2013.

Antiplatelet regimens after ischemic stroke or transient ischemic attack: a systematic review and updated network meta-analysis
CONCLUSIONS: The efficacy and safety profiles among antiplatelet regimens may differ according to clinical situation, although cilostazol, aspirin plus clopidogrel, and aspirin plus dipyridamole may be considered as preferable options.PMID:35402589 | PMC:PMC8987873 | DOI:10.21037/atm-21-3748
Source: Atherosclerosis - April 11, 2022 Category: Cardiology Authors: Seung Jin Jung Bum Joon Kim Chi Kyung Kim Sung Ryul Shim Jin-Man Jung Source Type: research

Sex Difference in the Impact of Dual Antiplatelet Therapy using Cilostazol for Secondary Stroke Prevention: A Sub-Analysis of CSPS.com
CONCLUSIONS: Long-term DAPT using cilostazol reduced the recurrence of ischemic stroke and prolonged the recurrence-free time in male patients, but not in female patients.PMID:36070920 | DOI:10.5551/jat.63660
Source: Journal of Atherosclerosis and Thrombosis - September 7, 2022 Category: Cardiology Authors: Haruhiko Hoshino Kazunori Toyoda Katsuhiro Omae Kaito Takahashi Shinichiro Uchiyama Kazumi Kimura Keiji Yamaguchi Kazuo Minematsu Hideki Origasa Takenori Yamaguchi CSPS.com Trial Investigators Source Type: research

Dual Versus Mono Antiplatelet Therapy in Patients with Acute Mild-to-Moderate Stroke: A Multicentre Perspective Cohort Study
ConclusionAspirin plus clopidogrel was associated with a reduction in the incidence of disability attributed to index stroke. There was no statistically significant difference in the incidence of moderate to severe bleeding complications between the two antiplatelet drug regimens.Trial Registration NumberChiCTR1900025214.
Source: Cardiovascular Drugs and Therapy - June 13, 2023 Category: Cardiology Source Type: research

Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE): 1-Year Outcomes.
CONCLUSIONS: -The early benefit of clopidogrel-aspirin treatment in reducing the risk of subsequent stroke persisted over the duration of 1 year of follow-up. Clinical Trial Registration Information-www.clinicaltrials.gov. Identifier: NCT00979589. PMID: 25957224 [PubMed - as supplied by publisher]
Source: Circulation - May 8, 2015 Category: Cardiology Authors: Wang Y, Pan Y, Zhao X, Li H, Wang D, Johnston SC, Liu L, Meng X, Wang A, Wang C, Wang Y, CHANCE investigators Tags: Circulation Source Type: research

The changes of secondary prevention practice in Czech post-stroke patients between 2007 and 2012/13
In conclusion, despite substantial improvement in acute management, clinical practice in secondary prevention in post-stroke patients remains far from being optimal.
Source: Cor et Vasa - February 23, 2016 Category: Cardiology Source Type: research

Homocysteine Level Predicts Response to Dual Antiplatelet in Women With Minor Stroke or Transient Ischemic Attack: Subanalysis of the CHANCE Trial.
CONCLUSIONS: Homocysteine could be a potential biomarker to discriminate the effects of dual and single antiplatelet therapy in female patients with minor ischemic stroke or high-risk transient ischemic attack. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00979589. PMID: 31941381 [PubMed - as supplied by publisher]
Source: Arteriosclerosis, Thrombosis and Vascular Biology - January 15, 2020 Category: Cardiology Authors: Li J, Wang Y, Li H, Zuo Z, Lin J, Wang A, Zhao X, Liu L, Wang Y, CHANCE Investigators* Tags: Arterioscler Thromb Vasc Biol Source Type: research

A Clinical Update on Antiplatelet Therapy in Secondary Prevention of Ischemic Stroke
AbstractPurpose of ReviewAntiplatelet therapy remains the standard of care in secondary stroke prevention for non-cardioembolic ischemic stroke and transient ischemic attack. We aim to examine the use of antiplatelet agents in secondary prevention through highlighting relevant clinical trials and meta-analyses as well as providing commentary regarding our practice.Recent FindingsIn the POINT and CHANCE trials, dual antiplatelet therapy reduced recurrent stroke compared to aspirin monotherapy. Sub-analyses of these trials suggest that genetic polymorphisms could play a role in diminishing the effectiveness of clopidogrel. S...
Source: Current Cardiology Reports - August 19, 2021 Category: Cardiology Source Type: research

Efficacy and safety of percutaneous left atrial appendage closure to prevent thromboembolic events in atrial fibrillation patients with high stroke and bleeding risk
Conclusion Left atrial appendage closure in patients with non-valvular atrial fibrillation and high risk for stroke and bleeding events effectively prevented stroke and reduced cerebral ischemic events compared to expected stroke rate according to CHA2DS2-VASc Score. Dual antiplatelet therapy for 3 months reduced the rate of bleeding events compared to 6 months therapy with no increase of thrombotic events.
Source: Clinical Research in Cardiology - August 29, 2015 Category: Cardiology Source Type: research

Association of CYP2C19 Polymorphisms With Clopidogrel Reactivity and Clinical Outcomes in Chronic Ischemic Stroke.
CONCLUSIONS: Despite associations betweenCYP2C19variants and on-clopidogrel platelet reactivity, there was no significant difference in rates of CVEs in the chronic stroke phase among the 3 clopidogrel-metabolizing groups ofCYP2C19variants. PMID: 31006731 [PubMed - as supplied by publisher]
Source: Circulation Journal - April 18, 2019 Category: Cardiology Authors: Tanaka T, Yamagami H, Ihara M, Miyata T, Miyata S, Hamasaki T, Amano S, Fukuma K, Yamamoto H, Nakagawara J, Furui E, Uchiyama S, Hyun B, Yamamoto Y, Manabe Y, Ito Y, Fukunaga R, Abumiya T, Yasaka M, Kitagawa K, Toyoda K, Nagatsuka K Tags: Circ J Source Type: research

Aspirin plus Clopidogrel versus Aspirin Mono-Therapy for Ischemic Stroke: A Meta-Analysis.
CONCLUSIONS: The addition of clopidogrel to aspirin for patients with TIA or IS appeared to significantly reduce the risk of IS recurrence with a possible increase in the risk of bleeding compared with aspirin alone. PMID: 31112048 [PubMed - as supplied by publisher]
Source: Scandinavian Cardiovascular Journal - May 23, 2019 Category: Cardiology Tags: Scand Cardiovasc J Source Type: research

P2Y12 Reaction Units and Clinical Outcomes in Acute Large Artery Atherosclerotic Stroke: A Multicenter Prospective Study
CONCLUSIONS: Acute PRU evaluation possesses predictive value for recurrent ischemic stroke, especially within 7 days in AIS/TIA with LAA.PMID:35249906 | DOI:10.5551/jat.63369
Source: Journal of Atherosclerosis and Thrombosis - March 7, 2022 Category: Cardiology Authors: Kazuki Fukuma Hiroshi Yamagami Masafumi Ihara Tomotaka Tanaka Toshiyuki Miyata Shigeki Miyata Koichi Kokame Kunihiro Nishimura Yuriko Nakaoku Haruko Yamamoto Mikito Hayakawa Kenji Kamiyama Yukiko Enomoto Ryo Itabashi Eisuke Furui Yasuhiro Manabe Masayuki Source Type: research